Establishing the prevalence of c-Met protein OE, its overlap with other known NSCLC biomarkers and MET genomic alterations (e.g. MET amplification), and its relevance to prognosis are crucial to fully understanding the potential benefits of c-Met–targeting ADCs in advanced NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.